The invention relates to the field of medicine and pharmacology, and specifically to a novel use of buspirone or a pharmaceutically acceptable salt thereof for treating functional dizziness, persistent postural-perceptual dizziness (PPPD), phobic postural vertigo (PPV), and chronic subjective dizziness (CSD), the effect of the invention lying in the possibility of treating functional dizziness that is independent of depressive and anxious states, a clinically optimal speed of onset of therapeutic action, ease of dose titration, a lack of a sedative effect, and a favorable safety profile.